The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew)

Physiology and Behavior

Volumn 97, Issue 1, 2009, Pages 121-124

  Parker, L A ^a   Limebeer, C L ^a   Rock, E M ^a   Litt, D L ^a   Kwiatkowska, M ^a   Piomelli, D ^b  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; Emesis; Endocannabinoid; FAAH; Nicotine; Shrew

Indexed keywords

ANANDAMIDE; CISPLATIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; NICOTINE; RIMONABANT;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; SHREW; VOMITING;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CARBAMATES; CISPLATIN; DRUG INTERACTIONS; FEMALE; MALE; NICOTINE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SHREWS; VOMITING;

EID: 62749092023     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2009.02.014     Document Type: Article

References (27)

1. Parker L.A., Limebeer C.L., and Kwiatkowska M. Effects of cannabinoids on vomiting and nausea in animal models. In: Mechoulam R. (Ed). Cannabinoids as therapeutics: milestones in drug therapy (2005), Birkhauser Publishing, Basle 183-201
2. Parker L.A., and Limebeer C.L. Cannabinoids in the management of nausea and vomiting. In: Kofalvi A. (Ed). Cannabinoids and the brain (2007), Springer-Verlag Press 259-277
3. Tramer M.R., Carroll D., Campbell F.A., Reynolds D.J.M., Moore R.A., and McQuay H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 (2001) 1-8
4. Feigenbaum J.J., Richmond S.A., Weissman Y., and Mechoulam R. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 4 (1989) 159-165
5. Simoneau I.I., Hamza M.S., Mata H.P., Siegel E.M., Vanderah T.W., Porreca F., et al. The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94 (2001) 882-886
6. Van Sickle M.D., Oland L.D., Ho W., Hillard C.J., Mackie K., Davison J.S., et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121 (2001) 767-774
7. McCarthy L.E., and Borison H.L. Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol 21 (1981) 30S-37S
8. Darmani N.A. Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24 (2001) 198-203
9. Kwaitkowska M., Parker L.A., Burton P., and Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174 (2004) 254-259
10. Parker L.A., Kwaitkowska M., Burton P., and Mechoulam R. Effect of cannabinoids on lithum-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171 (2004) 156-161
11. Darmani N.A. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta (9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 300 (2002) 34-42
12. Hornby P.J. Central neurocircuitry associated with emesis. Am J Med 111 Suppl 8A (2001) 106S-112S
13. Van Sickle M.D., Oland L.D., Mackie K., Davison J.S., and Sharkey K.A. Δ9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285 (2003) G566-G576
14. Van Sickle M.D., Oland L.D., Ho W., Hillard C.J., Mackie K., Davison J.S., et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121 (2001) 767-774
15. Devane W.A., Hanus L., Bruer A., Pertwe R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
16. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46 (1993) 791-796
17. Piomelli D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4 (2003) 873-884
18. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 (2005) 352-358
19. Sharkey K.A., Cristino L., Oland L.D., Van Sickle M.D., Starowicz K., Pittman Q.J., et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25 (2007) 2773-2782
20. Darmani N.A., McClanahan V.A., Trinh C., Petrosino S., Valenti M., and DiMarzo V. Cisplatin increases brain 2-arachidonylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 48 (2005) 1154-1163
21. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
22. Cross-Mellor S.K., Ossenkopp K.P., Piomelli D., and Parker L.A. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology 190 (2007) 135-143
23. Parker L.A., Rana S.A., and Limebeer C.L. Conditioned disgust, but not conditioned taste avoidance: a measure of conditioned nausea in rats. Can J Exp Psych 62 (2008) 198-209
24. Rock E.M., Limebeer C.L., Mechoulam R., Piomelli D., and Parker L.A. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196 (2008) 389-395
25. Limebeer C.L., Krohn J.P., Cross-Mellor S., Ossenkopp K.P., and Parker L.A. Exposure to a context previously associated with toxin (LiCl)- or motion-induced sickness elicits conditioned gaping in rats: evidence in support of a model of anticipatory nausea. Behav Brain Res 187 (2008) 33-40
26. Parker L.A., Kwiatkowska M., and Mechoulam R. Delta-9-Tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87 (2006) 66-71
27. Hickok J.T., Roscoe J.A., Morrow G.R., King D.K., Atkins J.N., and Fitch T.R. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-Hydroxytryptamine-3 antiemetics. Cancer 97 (2003) 2880-2886